Silexion Therapeutics Announces Exercise of Warrants

Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. NASDAQ:SLXN (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immedia…